A specific malaria parasite mutation called PfDHFR I164L, which causes resistance to sulfadoxine-pyrimethamine (SP), increased from 19.4% to 32.4% of malaria cases in Uganda between 2016 and 2022, according to Gram Research analysis of 4,725 parasite samples. This mutation is spreading unevenly across different regions and through multiple genetic pathways, suggesting drug resistance is becoming a growing challenge for malaria prevention programs.
Scientists studying malaria in Uganda discovered that a specific genetic mutation called PfDHFR I164L is becoming more common in the parasite that causes malaria. This mutation makes the parasite resistant to sulfadoxine-pyrimethamine (SP), a key antimalarial drug used to prevent malaria in pregnant women and children. Researchers analyzed nearly 5,000 malaria samples collected from 2016 to 2022 and found the mutation increased from about 19% to 32% over that time period. The mutation is spreading differently in different areas of Uganda, which suggests the problem is complex and may require different solutions in different regions.
Key Statistics
A 2026 research article analyzing 4,725 malaria parasite samples from Uganda found that the PfDHFR I164L resistance mutation increased from 19.4% in 2016 to 32.4% in 2022, representing a 68% relative increase in drug-resistant parasites over six years.
According to a Nature Communications study of malaria surveillance in Uganda, the PfDHFR I164L mutation appeared on multiple different genetic backgrounds rather than spreading as a single genetic variant, indicating that drug resistance is evolving through complex, independent pathways.
Gram Research analysis of 16 Ugandan health facilities found that antimalarial drug resistance spread geographically unevenly, with different clinics showing different rates of resistance increase, suggesting that local factors significantly influence how quickly resistance develops in different areas.
The Quick Take
- What they studied: How a specific genetic change in malaria parasites makes them resistant to an important antimalarial drug, and whether this resistance is spreading across Uganda.
- Who participated: Nearly 4,725 malaria parasite samples collected from 16 health clinics across Uganda between 2016 and 2022, representing routine malaria surveillance.
- Key finding: The PfDHFR I164L mutation, which causes drug resistance, increased from 19.4% to 32.4% of malaria cases over six years. This mutation appeared on different genetic backgrounds and spread unevenly across different areas.
- What it means for you: If you live in or travel to Uganda, this research suggests malaria prevention drugs may become less effective over time. However, this doesn’t mean the drugs stop working immediately—it means health officials need to monitor resistance and potentially adjust prevention strategies. Talk to your doctor about current malaria prevention recommendations for your specific location.
The Research Details
Researchers collected malaria parasite samples from 16 health clinics across Uganda over six years (2016-2022). They examined the genetic code of nearly 4,725 parasites, looking for eight specific mutations known to cause drug resistance. They used advanced genetic analysis techniques to understand how these mutations were inherited and spread through the parasite population.
The scientists used three main analytical approaches: they looked at how closely related different parasites were to each other (identity-by-descent analysis), they examined the patterns of genetic variations (haplotype structure), and they studied how long stretches of identical DNA were shared between parasites (extended haplotype homozygosity). These techniques helped them understand whether the resistance mutations were spreading because they gave parasites a survival advantage or simply because they were being passed along randomly.
This type of surveillance study is crucial for public health because it tracks how drug resistance evolves in real populations over time, rather than just in laboratory settings.
Understanding how drug resistance spreads geographically and genetically helps health officials predict where problems might occur next and decide whether to change prevention strategies. By tracking these mutations over time in actual communities, researchers can see the real-world impact of antimalarial drug use on parasite populations.
This study has several strengths: it examined a large number of samples (4,725) from multiple locations over a six-year period, providing solid evidence of trends. The research was published in Nature Communications, a highly respected scientific journal. However, the study focused only on Uganda, so results may not apply to other regions. The researchers also note that they couldn’t detect clear signs of natural selection at most locations, suggesting the resistance spread through other mechanisms like migration or chance, which makes predictions more difficult.
What the Results Show
The most important finding was that PfDHFR I164L, a mutation that makes malaria parasites highly resistant to pyrimethamine (a key antimalarial drug), increased significantly over the study period. In 2016, this mutation was found in about 19.4% of malaria samples, but by 2022, it had increased to 32.4%—a substantial rise in just six years.
Interestingly, the researchers discovered that this mutation wasn’t simply spreading as a single genetic package. Instead, it appeared on multiple different genetic backgrounds, meaning the mutation arose independently in different parasite populations or was shuffled into different genetic combinations through recombination. This complexity suggests the resistance isn’t spreading through a single “super-parasite” but rather through multiple independent evolutionary events.
The spread of this mutation was also geographically uneven. Different health clinics across Uganda showed different patterns of resistance increase. Some areas showed rapid increases while others showed slower changes, suggesting that local factors—like how much the drug is used, how many people have malaria, and how parasites move between areas—all influence resistance development.
The study also examined other resistance mutations in the pfdhfr and pfdhps genes. While PfDHFR I164L was the star of the show, the researchers found that other mutations were also present and changing over time, though generally at slower rates. The combination of multiple mutations in the same parasite can create even higher levels of drug resistance, which is concerning for future malaria control.
Previous research has shown that drug resistance mutations emerge and spread in malaria parasites, but this study provides more detailed information about how this happens in real populations. Earlier studies suggested that certain mutations would spread rapidly due to natural selection, but this research shows the picture is more complicated—resistance can spread through multiple mechanisms and at different rates in different places. This finding challenges some previous assumptions about how predictable drug resistance evolution is.
The study focused only on Uganda, so the findings may not apply to other countries with malaria. The researchers couldn’t determine exactly why the mutation was spreading—whether it was because it gave parasites a survival advantage, because of how people moved around, or simply by chance. They also note that surveillance data comes from health clinics, which may not represent all malaria cases in the community. Additionally, the study shows correlation (the mutation increased over time) but can’t definitively prove causation (that specific factors caused the increase).
The Bottom Line
Health officials in Uganda should continue monitoring drug resistance mutations regularly to catch changes early. Current antimalarial drugs remain effective, but resistance is increasing and may eventually require switching to different drugs or combination therapies. Pregnant women and children in Uganda should continue using sulfadoxine-pyrimethamine for malaria prevention as currently recommended, but health programs should prepare contingency plans for alternative drugs. Confidence level: High for the need to monitor; Moderate for specific policy changes, as this depends on additional factors beyond this single study.
This research is most relevant to: (1) people living in or traveling to Uganda, especially pregnant women and young children who rely on SP for malaria prevention; (2) malaria control programs and public health officials in Uganda and similar regions; (3) pharmaceutical companies developing new antimalarial drugs; (4) global health organizations tracking drug resistance trends. People in malaria-free regions should be aware of this as a global health issue but don’t need to change personal behavior based on this study.
Drug resistance typically develops gradually over years to decades. The increase from 19% to 32% over six years suggests resistance is accelerating but hasn’t yet reached crisis levels. Health officials likely have several years to monitor the situation and plan responses, but action should begin now rather than waiting for resistance to become widespread.
Frequently Asked Questions
Is malaria drug resistance getting worse in Uganda?
Yes. The PfDHFR I164L resistance mutation increased from 19.4% to 32.4% between 2016 and 2022 in Uganda. However, current antimalarial drugs still work; resistance is developing gradually, giving health officials time to plan responses.
What does the I164L mutation do to malaria parasites?
This mutation changes a protein in malaria parasites that normally gets blocked by pyrimethamine, an antimalarial drug. With the mutation, the drug can’t block the protein effectively, allowing resistant parasites to survive treatment.
Why is malaria drug resistance spreading differently in different parts of Uganda?
The study found that resistance spreads unevenly across regions, likely due to differences in drug use patterns, parasite transmission rates, population movement, and local environmental factors. This complexity makes predicting resistance spread challenging.
Should pregnant women in Uganda stop taking antimalarial prevention?
No. Sulfadoxine-pyrimethamine remains effective for malaria prevention despite increasing resistance. Continue taking it as recommended by your healthcare provider, but health officials are monitoring resistance to plan future strategies.
How does this Uganda study affect malaria treatment worldwide?
This study shows how drug resistance evolves in high-transmission settings. Similar resistance patterns may develop in other malaria-endemic regions, so global health programs are using this research to prepare alternative strategies and monitor resistance globally.
Want to Apply This Research?
- If you live in Uganda or travel there regularly, track your malaria prevention adherence: log each dose of antimalarial medication taken, note any malaria symptoms that develop despite prevention, and record your location. This personal data helps identify whether prevention is working in your area.
- Set daily reminders to take antimalarial medications as prescribed, especially if you’re pregnant or have young children. Use the app to log doses and share adherence data with your healthcare provider to ensure you’re getting maximum protection from available drugs.
- Over months and years, track whether malaria cases increase in your area despite consistent drug use. Share this information with local health clinics, as patterns of treatment failure help officials detect emerging drug resistance early.
This research describes emerging drug resistance in malaria parasites in Uganda and does not constitute medical advice. Pregnant women, children, and travelers should continue taking antimalarial medications as prescribed by their healthcare providers. If you live in or travel to Uganda, consult with a healthcare professional about current malaria prevention recommendations for your specific location and circumstances. This study was conducted in Uganda and may not apply to other regions. Do not change your malaria prevention strategy based on this article alone—always discuss any changes with your doctor.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.